InvestorsHub Logo
Followers 12
Posts 471
Boards Moderated 0
Alias Born 06/20/2020

Re: Michel post# 370531

Monday, 08/16/2021 11:07:00 AM

Monday, August 16, 2021 11:07:00 AM

Post# of 403051
Yeah, seeking EUA on 12 subjects treated in their P2. Got go-ahead for P3 on Aug 5th.

In P2, age group >85 years, 91% of those treated survived. Still, they had just 12 subjects in the treatment arm. Will be interesting to see how this goes.

Here's the paper with P2 results, including AEs, etc.: Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial

BTW: The company was formed in 2007, has 4 employees, a market cap of $140m, and trades on the OTC. They're up >500% in 1 year.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News